UCB S.A. (UCB) is a global biopharmaceutical company, with a focus on neurology and immunology. Our total revenue grew to €4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.
UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are also leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.
UCB will contribute to both in vitro and in vivo research work packages, including:
- bioinformatics and network analyses of integrated transcriptomic and proteomic data,
- validating in vitro mitochondrial signatures in in vivo models, and
- validating mitochondrial signatures in patient samples and other models of Parkinson’s disease.